0102030405
SLU-PP-915 CAS 2285432-92-8 ERR Agonist for Metabolic Research - Quality Products from China Suppliers & Factory
Brief Introduction
- Novel mitochondrial metabolism modulator
- Designed for advanced obesity & metabolic disorder research
- Potential thermogenic pathway activator
- High purity ≥98% (HPLC)
- Stable powder form, scalable synthesis
- Suitable for in vitro & preclinical studies
- Reliable bulk supply from China manufacturer
- Custom synthesis & COA available
SLU-PP-915 (development code: 915) is a pan-estrogen-related receptor (pan-ERR) agonist developed by Saint Louis University and other institutions through a structure-based drug design approach. It is a next-generation compound structurally optimized from the well-studied SLU-PP-332, with the key improvement being the introduction of a boronic acid moiety that confers the critical advantage of oral bioavailability. SLU-PP-915 simultaneously activates all three ERR isoforms (α, β, and γ), regulating core metabolic processes such as mitochondrial biogenesis, fatty acid oxidation, and oxidative phosphorylation, and is regarded as a promising "exercise mimetic."
Key Scientific Value & Findings
💊 Oral Bioavailability — A Key Breakthrough
The first-generation compound SLU-PP-332, while effective, lacked oral bioavailability, limiting its application in chronic dosing studies. SLU-PP-915, through structural optimization (incorporating a boronic acid group), exhibits significantly improved metabolic stability, making it the first orally active, potent pan-ERR agonist.
🏃 Enhanced Aerobic Exercise Capacity
Studies show that when administered intraperitoneally, SLU-PP-915 enhances aerobic exercise performance (distance and duration) in mice to an extent similar to SLU-PP-332. Importantly, this efficacy is maintained when administered orally after adjusting for systemic exposure, demonstrating excellent oral activity. This highlights its significant potential as an oral "exercise mimetic."
❤️ Improved Cardiac Function in Heart Failure
In a mouse model of pressure overload-induced heart failure, treatment with SLU-PP-915 (and SLU-PP-332) significantly improved ejection fraction, ameliorated fibrosis, and increased survival without affecting cardiac hypertrophy. The mechanism involves transcriptional activation of metabolic gene networks involved in fatty acid metabolism and mitochondrial function, leading to substantial normalization of metabolic profiles for fatty acids/lipids and TCA/oxidative phosphorylation metabolites in the heart.
🧬 Activation of ERR Target Genes
SLU-PP-915 potently upregulates the expression of ERR target genes such as DNA damage-inducible transcript 4 (Ddit4), PGC-1α, lactate dehydrogenase A (LDHA), and pyruvate dehydrogenase kinase 4 (PDK4), which play central roles in energy metabolism of skeletal muscle and heart.
⚡ Synergy with Exercise Training
Notably, SLU-PP-915 synergizes with actual exercise training to further enhance the expression of Ddit4 and mitochondrial genes. This provides a basis for studying the potential applications of combining pharmacological intervention with exercise.
🔎 ERRγ as the Primary Mediator
In vitro and in vivo genetic dependency experiments have demonstrated that ERRγ is the primary mediator of ERR agonist-induced transcriptional regulation and cardioprotection.
Our Supply & Service Advantages
Frequently Asked Questions
What is SLU-PP-915 and how does it differ from SLU-PP-332?
SLU-PP-915 is a next-generation pan-ERR agonist structurally optimized from SLU-PP-332. The key difference is the introduction of a boronic acid moiety in SLU-PP-915, which confers oral bioavailability — a critical advantage that SLU-PP-332 lacked. Both compounds activate all three ERR isoforms (α, β, and γ), but SLU-PP-915 is suitable for chronic oral dosing studies.
What is the purity and available form of SLU-PP-915?
SLU-PP-915 is supplied as a stable powder with a purity of ≥98% as confirmed by HPLC analysis. A Certificate of Analysis (COA) is available upon request, and custom synthesis options are also offered to meet specific research requirements.
What research applications is SLU-PP-915 suitable for?
SLU-PP-915 is designed for in vitro and preclinical studies related to obesity, metabolic disorders, heart failure, and exercise physiology research. It is particularly valuable for investigating mitochondrial biogenesis, fatty acid oxidation, oxidative phosphorylation, and ERR-mediated transcriptional regulation.
Has SLU-PP-915 demonstrated efficacy in animal models?
Yes. In preclinical mouse studies, SLU-PP-915 has demonstrated enhanced aerobic exercise performance, improved cardiac ejection fraction, reduced fibrosis, and increased survival in heart failure models. These effects were observed with both intraperitoneal and oral administration routes.
Can SLU-PP-915 be combined with exercise training in research studies?
Research findings indicate that SLU-PP-915 synergizes with actual physical exercise training to further enhance the expression of key mitochondrial genes such as Ddit4. This makes it a valuable tool for studying the combined effects of pharmacological intervention and exercise on metabolic health.
Is bulk supply and custom synthesis of SLU-PP-915 available?
Yes. As a reliable China-based manufacturer, we offer scalable synthesis and bulk supply of SLU-PP-915 to support research institutions and pharmaceutical companies. Custom synthesis, specific packaging, and COA documentation are all available upon request.